Read the Tesamorelin Research Guide. Review the research context and evidence limitations.
Tesamorelin (10 mg Vial) is supplied for controlled laboratory evaluation of Tesamorelin within Growth Hormone Research studies.
- Research material: Tesamorelin
- Listed strength and format: 10 mg Vial
- Research category: Growth Hormone Research
Tesamorelin identity and comparison research
Tesamorelin is a modified growth hormone-releasing hormone (GHRH) analogue. The FDA chemistry review for tesamorelin describes a 44-amino-acid sequence with an N-terminal hexenoyl modification. This structural reference concerns the compound; it does not certify this SRP vial or make it the branded Egrifta medicine.
For compound-selection comparisons, Sermorelin is a distinct GHRH(1-29)-amide fragment. Shared research categories do not make their sequences or experimental results interchangeable.
Review the 10 mg vial and its documentation
The listing describes 10 mg of material in a 3 mL container. Container capacity is not a prepared concentration. Check that the linked laboratory report matches the lot being supplied, including identity and measured content. Contact SRP for current-lot documentation before selecting material for a protocol.
For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.
